Obsessive-Compulsive Disorder
OCD is characterised by recurrent obsessions (intrusive thoughts) and/or compulsions (repetitive behaviours) causing significant distress. Lifetime prevalence is approximately 2-3%.
Key Facts
- Obsessions are recurrent, unwanted intrusive thoughts, images, or urges that cause marked anxiety
- Compulsions are repetitive behaviours or mental acts performed to reduce anxiety caused by obsessions
- Lifetime prevalence ~2-3%; equal sex ratio; bimodal onset (childhood/early adulthood)
- First-line treatment: CBT with exposure and response prevention (ERP) ± SSRI (NICE CG31)
- SSRI doses for OCD are typically higher than for depression (e.g., fluoxetine 60-80mg, sertraline 200mg)
- Clomipramine (TCA) is the most effective single agent for OCD but has more side effects - second-line
- Y-BOCS (Yale-Brown Obsessive Compulsive Scale) is the gold standard severity measure
- Common themes: Contamination/washing, harm/checking, symmetry/ordering, forbidden thoughts (religious, sexual, aggressive)
Overview
Key Facts
OCD is a chronic neuropsychiatric disorder characterised by obsessions and compulsions that are time-consuming, distressing, and functionally impairing. It is one of the most disabling psychiatric conditions.
Epidemiology
Lifetime prevalence is 2-3%. Equal sex distribution overall, but males have earlier onset. Mean age of onset is 19-20 years (bimodal: childhood peak ~10 years, adult peak ~21 years). Average delay to treatment is 7-10 years. OCD accounts for significant disability - ranked by WHO as one of the top 10 most disabling conditions.
Aetiology
- Genetic: Heritability ~40-50%; first-degree relatives have 4× increased risk
- Neuroanatomical: Cortico-striato-thalamo-cortical (CSTC) circuit dysfunction - orbitofrontal cortex and caudate nucleus hyperactivity
- Serotonergic: Serotonin dysfunction - basis for SSRI treatment
- Autoimmune: PANDAS (Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) - abrupt OCD onset post-streptococcal infection in children
- Psychological: Inflated responsibility beliefs, thought-action fusion, intolerance of uncertainty
Pathophysiology
- CSTC circuit model: Overactivity in orbitofrontal cortex → excessive error signalling → "something is wrong" feeling → compulsive behaviour to reduce anxiety
- Serotonin hypothesis: Supported by selective response to serotonergic drugs (SSRIs, clomipramine) but not noradrenergic drugs
- Glutamate dysfunction: Emerging evidence - riluzole and memantine under investigation
- ERP mechanism: Habituation - repeated exposure to anxiety-provoking stimuli without performing compulsion leads to anxiety reduction over time
Clinical Presentation
Common Obsession Themes
- Contamination: Fear of germs, dirt, bodily fluids → washing/cleaning compulsions
- Harm: Fear of causing harm to self or others → checking compulsions
- Symmetry/ordering: Need for things to be "just right" → arranging, counting
- Forbidden thoughts: Intrusive sexual, religious, or aggressive thoughts → mental rituals, reassurance-seeking
Common Compulsion Types
- Washing and cleaning
- Checking (locks, appliances, safety)
- Counting, ordering, arranging
- Mental rituals (praying, repeating words)
- Reassurance-seeking
- Hoarding (may overlap with hoarding disorder)
Key Clinical Features
- Patient recognises thoughts are their own (not inserted) and usually recognises they are excessive/irrational
- Attempts to resist compulsions cause mounting anxiety
- Symptoms are time-consuming (>1 hour/day) and cause significant distress or functional impairment
Red Flags
- Severe OCD with total functional impairment - consider specialist inpatient OCD unit
- OCD with psychotic features - poor insight subtype, consider antipsychotic augmentation
- Sudden onset OCD in child post-streptococcal infection - PANDAS, consider paediatric referral
- Suicidal ideation - comprehensive risk assessment
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| GAD | Excessive worry about real-life concerns (not ego-dystonic) | GAD-7, clinical assessment |
| Body dysmorphic disorder | Preoccupation with perceived physical defect | Clinical assessment |
| Illness anxiety disorder | Preoccupation with having serious illness | Clinical assessment |
| Tic disorder/Tourette's | Motor/vocal tics; may coexist with OCD | Clinical observation |
| Psychotic disorder | Delusions (ego-syntonic, not resisted) | MSE, psychiatric assessment |
| Autism spectrum disorder | Rigid routines and rituals, but not distressing | Developmental history, ADOS |
| Anankastic personality disorder | Pervasive perfectionism, rigidity - ego-syntonic | Personality assessment |
Diagnosis / Investigation
Bedside
- Y-BOCS: Gold standard severity rating (0-40); mild <16, moderate 16-23, severe 24-31, extreme 32-40
- OCI-R (Obsessive-Compulsive Inventory-Revised): Self-report screening tool
- PHQ-9/GAD-7: Screen for comorbid depression and anxiety
- Risk assessment: Suicidal ideation, self-harm
Bloods
- TFTs: Exclude thyroid dysfunction
- FBC: Baseline if starting clomipramine
- ASOT/anti-DNase B: If PANDAS suspected in children
Special Tests
- ECG: Before clomipramine (cardiotoxic); baseline for SSRIs at high doses
- Neuropsychological testing: If cognitive concerns or diagnostic uncertainty
- Neuroimaging: Not routine - research shows OFC and caudate hyperactivity on fMRI
Management
Non-pharmacological
- Mild OCD: Low-intensity CBT (guided self-help with ERP)
- Moderate-severe OCD: High-intensity CBT with ERP (specialist therapist, 12-20 sessions)
- ERP protocol: Graded exposure to feared stimuli + prevention of compulsive response → habituation
- Family involvement: Psychoeducation, reducing accommodation of compulsions
Pharmacological (NICE CG31)
- First-line SSRI (higher doses than for depression):
- Fluoxetine 60-80mg OD
- Sertraline 200mg OD
- Fluvoxamine 100-300mg OD
- Paroxetine 40-60mg OD
- Allow 8-12 weeks at adequate dose before concluding ineffective (longer than depression)
- Second-line: Clomipramine 75-250mg OD (most effective single agent, but anticholinergic/cardiac side effects)
- Augmentation (specialist): Low-dose antipsychotic (risperidone 0.25-2mg, aripiprazole 5-15mg) added to SSRI
- Treatment duration: Continue for ≥12 months after remission; gradual tapering
Referral Criteria
- Moderate-severe OCD - secondary care for CBT with ERP and SSRI optimisation
- Treatment-resistant OCD (failed 2 SSRI trials + CBT) - specialist OCD service
- Severe functional impairment - specialist/inpatient OCD unit
- PANDAS - paediatric neurology/psychiatry
Prognosis
- CBT with ERP: 60-70% response rate; gains well-maintained with continued practice
- SSRIs: 40-60% response rate; high relapse rate on discontinuation (~50%)
- Combined CBT + SSRI: Best outcomes, especially for moderate-severe OCD
- Course: Chronic and relapsing in most cases; ~20% have a chronic unremitting course
- Predictors of poor outcome: Early onset, poor insight, hoarding symptoms, comorbid depression, family history
- Functional recovery: Even with symptom reduction, many patients have residual functional impairment
Other Relevant Information
Y-BOCS Severity
| Score | Severity |
|---|---|
| 0-7 | Subclinical |
| 8-15 | Mild |
| 16-23 | Moderate |
| 24-31 | Severe |
| 32-40 | Extreme |
NICE CG31 Stepped Care
| Step | Severity | Intervention |
|---|---|---|
| 1 | Mild | Guided self-help with ERP (6-8 weeks) |
| 2 | Mild (failed step 1) | Brief CBT with ERP or SSRI |
| 3 | Moderate | CBT with ERP (including ERP) + SSRI |
| 4 | Severe/treatment-resistant | Specialist OCD unit, clomipramine, augmentation, consider neurosurgery (last resort) |